Fortunato Rocca

Zoetis Products LLC engaged in the manufacturing of pharmaceutical products. The company was founded in 1975 and was headquartered in Florham Park, NJ.

Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ.

Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA.

Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA.

Circular Genomics, Inc. is a company that specializes in the development of circular RNA-based precision medicine tools, data, and diagnostics for neurology and psychiatry. The company is based in Albuquerque, NM. The company is focused on disrupting and improving the standard of care for major depressive disorder and other neurological diseases. The company offers assays that can assess and direct the best treatment protocol for an individual patient and validate treatment effectiveness in days-to-weeks rather than months. The company was founded in 2021 by Alexander Hafez, Kosmas Karadimitriou, and Nikolaos Mellios. Paul Sargeant has been the CEO of the company since 2023.